Roche enlists Alector in Parkinson's deal, paying $100M upfront
Alector is teaming up with another large drugmaker, fresh off a separate partnership collapsing. Alector will get $100 million upfront from Roche in a deal centered on the biotech’s neuroscience and Parkinson’s disease efforts. If ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.